The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
-sheet, or coil secondary structures. Backbone-dependent rotamer libraries present conformations and/or frequencies dependent on the local backbone conformation as defined by the backbone dihedral angles
Bryant Park is a 9.6-acre (3.9 ha), privately managed public park in the New York City borough of Manhattan. It is located between Fifth Avenue and Avenue of the Americas (Sixth Avenue) and between 40th and 42nd Streets in Midtown Manhattan. The eastern half of Bryant Park is occupied by the Main Branch of the New York Public Library. The western half contains a lawn, shaded walkways, and amenities such as a carousel, and is located entirely over an underground structure that houses the library's stacks. The park hosts several events, including a seasonal "Winter Village" with an ice rink and shops during the winter. The first park at the site was opened in 1847 and was called Reservoir Square due to its proximity to the Croton Distributing Reservoir. Reservoir Square contained the New York Crystal Palace, which hosted the Exhibition of the Industry of All Nations in 1853 and burned down in 1858. The square was renamed in 1884 for abolitionist and journalist William Cullen Bryant. The reservoir was demolished in 1900 and the New York Public Library's main branch was built on the site, opening in 1911. Bryant Park was rebuilt in 1933–1934 to a plan by Lusby Simpson. After a period of decline, it was restored in 1988–1992 by landscape architects Hanna/Olin Ltd. and architects Hardy Holzman Pfeiffer Associates, during which the park was rebuilt and the library's stacks were built underneath. Further improvements were made in the late 20th and early 21st centuries.
== Ex vivo or in vivo methods == Methods that screen protein–protein interactions in the living cells. Bimolecular fluorescence complementation (BiFC) is a technique for observing the interactions of proteins. Combining it with other new techniques, dual expression recombinase based (DERB) methods can enable the screening of protein–protein interactions and their modulators. The yeast two-hybrid screen investigates the interaction between artificial fusion proteins inside the nucleus of yeast. This approach can identify the binding partners of a protein without bias. However, the method has a notoriously high false-positive rate, which makes it necessary to verify the identified interactions by co-immunoprecipitation.
However, major drawbacks of SMB are the inability of separating a mixture into three fractions and the lack of solvent gradient applicability. In the case of antibodies, the state-of-the-art technique is based on batch affinity chromatography (with Protein A or Protein G as ligands) which is able to selectively bind antibody molecules. In general, affinity techniques have the advantage of purifying biomolecules with high yields and purities but the disadvantages are in general the high stationary phase cost, ligand leaching and reduced cleanability. The MCSGP process can result in purities and yields comparable to those of purification using Protein A. The second application example for the MCSGP prototype is the separation of three MAb variants using a preparative weak cation-exchange resin. Although the intermediately eluting MAb variant can only be obtained with 80% purity at recoveries close to zero in a batch chromatographic process, the MCSGP process can provide 90% purity at 93% yield. A numerical comparison of the MCSGP process with the batch chromatographic process, and a batch chromatographic process including ideal recycling, has been performed using an industrial polypeptide purification as the model system. It shows that the MCSGP process can increase the productivity by a factor of 10 and reduce the solvent requirement by 90%.
Sources: en.wikipedia.org
"Attogram sensing of trinitrotoluene with a self-assembled molecular gelator". Journal of the American Chemical Society. 134 (10): 4834–4841. doi:10.1021/ja210728c. PMID 22352376. SS Babu, VK Praveen, Ajayaghosh, Ayyappanpillai (2014). “Functional π-gelators and their applications”. Chem. Rev. 2014, 114, 4, 1973-2129. https://doi.org/10.1021/cr400195e R, D, Mukhopadhyay.; and Ajayaghosh, Ayyappanpillai (2015). “Living supramolecular polymerization”. Science 2015, 349, 241.doi:10.1126/science.aac7422 S, Prasanthkumar.; S, Ghosh.; V, C, Nair.; A, Saeki.; S, Seki.; and Ajayaghosh Ayyappanpillai (2015). “Organic Donor-Acceptor Assemblies to Coaxial p-n Heterojunctions with High Photoconductivity”. Angew. Chem., Int. Ed. 2015, 54, 946-950. https://doi.org/10.1002/anie.201408831. B, Vedhanarayanan.; V, S, Nair.; V, C, Nair.; and Ajayaghosh, Ayyappanpillai (2016). “Formation of Coaxial Nanocables with Amplified Supramolecular Chirality through an Interaction between Carbon Nanotubes and a Chiral p-Gelator”. Angew. Chem., Int. Ed. 2016, 55, 10345-10349. https://doi.org/10.1002/anie.201605354. V, S, Nair.; R, D, Mukhopadhyay.; A, Saeki.; S, Seki.; and Ajayaghosh, Ayyappanpillai (2016). “A p-Gel Scaffold for Assembling Fullerene to Photoconducting Supramolecular Rods: Non-Equilibrium Self-Assembly of C60 in a p-Gel”. Science Advances 2016, 2, e1600142. doi:10.1126/sciadv.1600142 R, D, Mukhopadhyay.; B, Vedhanarayanan.; and Ajayaghosh, Ayyappanpillai (2017). “Creation of 'Rose Petal' and 'Lotus Leaf' Effects on Alumina by Surface Functionalization and Metal Ion Coordination”. Angew.
=== Cardiovascular disease === There is no evidence that vitamin C supplementation decreases the risk of cardiovascular disease, although there may be an association between higher circulating vitamin C levels or dietary vitamin C and a lower risk of stroke. There is a positive effect of vitamin C on endothelial dysfunction when taken at doses greater than 500 mg per day. (The endothelium is a layer of cells that line the interior surface of blood vessels.)
Doxepin acts as a Serotonin–norepinephrine reuptake inhibitor, (SNRI), and has additional antiadrenergic, antihistamine, antiserotonergic, and anticholinergic activities. It is specifically an antagonist of the histamine H1 and H2 receptors, the serotonin 5-HT2A and 5-HT2C receptors, the α1-adrenergic receptor, and the muscarinic acetylcholine receptors (M1–M5). Similarly to other tricyclic antidepressants, doxepin is often prescribed as an effective alternative to SSRI medications. Doxepin is also a potent blocker of voltage-gated sodium channels, and this action is thought to be involved in both its lethality in overdose and its effectiveness as an analgesic (including in the treatment of neuropathic pain, and as a local anesthetic). The potencies of doxepin in terms of its receptor antagonism specifically are as follows:
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.